SAGE Therapeutics

Biogen cuts ties with Sage on failed tremor drug
First Word Pharma
Thu, 09/26/24 - 11:03 am
Biogen
SAGE Therapeutics
SAGE-324
essential tremor
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
Pharma Voice
Mon, 07/29/24 - 10:29 am
SAGE Therapeutics
Biogen
clinical trials
SAGE-324
essential tremor
Zurzuvae
postpartum depression
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure
BioSpace
Wed, 07/24/24 - 11:55 am
Biogen
SAGE Therapeutics
clinical trials
essential tremors
BIIB124
SAGE-324
Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’
BioSpace
Tue, 06/11/24 - 10:51 pm
SAGE Therapeutics
dalzanemdor
clinical trials
Huntington's disease
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
BioSpace
Wed, 04/17/24 - 11:23 am
SAGE Therapeutics
clinical trials
Parkinson's Disease
dalzanemdor
A new $16,000 postpartum depression drug is here. How will insurers handle it?
Medical Marketing and Media
Wed, 03/13/24 - 11:11 am
zuranolone
postpartum depression
SAGE Therapeutics
Sage offers encouraging details on launch of new postpartum depression pill
BioPharma Dive
Wed, 02/14/24 - 06:42 pm
SAGE Therapeutics
postpartum depression
drug launches
Zurzuvae
In downsizing mode, Sage will move headquarters to a smaller space
Fierce Pharma
Thu, 01/25/24 - 11:17 am
SAGE Therapeutics
headquarters
Biogen
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
Reuters
Tue, 11/7/23 - 09:55 am
Biogen
SAGE Therapeutics
postpartum depression
drug pricing
Zurzuvae
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Fierce Biotech
Thu, 08/31/23 - 11:54 am
SAGE Therapeutics
layoffs
Biogen
major depressive disorcer
zuranolone
Brii Biosciences aims to come up big where Sage and Biogen fell short
Pharma Voice
Mon, 08/21/23 - 06:53 pm
Brii Biosciences
depression
SAGE Therapeutics
Biogen
BRII-296
postpartum depression
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Fierce Pharma
Mon, 08/7/23 - 12:01 pm
SAGE Therapeutics
Biogen
FDA
Zurzuvae
postpartum depression
major depressive disorder
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Sun, 08/6/23 - 09:39 pm
Biogen
SAGE Therapeutics
FDA
Zurzuvae
postpartum depression
major depressive disorder
zuranolone
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
Sat, 07/29/23 - 10:45 pm
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Sage Stock Drops Despite Promising Phase III Depression Data
BioSpace
Thu, 07/27/23 - 11:30 am
SAGE Therapeutics
zuranolone
Biogen
depression
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
2023’s biggest launches: the story so far
EP Vantage
Fri, 05/12/23 - 10:19 am
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals

Pages